The purpose of this study was to implement a model of permanent oral health care for oncopediatric patients and to observe its effects on severe oral mucositis and subsequent treatment interruptions. We performed a quasi-experimental study in the Pediatric Department of Napoleão Laureano Hospital, in the city of João Pessoa, Brazil. A integrated oral care was implemented by a dentistry team for prevention of comorbidities, such as infections, oral pain, oral function maintenance, oral mucositis, and interventions for lesions due to severe oral mucositis. The oral comorbidities were compared before and after the implementation. The duration of severe oral mucositis (SOM) before and after the interventions and the interruptions in treatment due to SOM were the main outcome measures. Permanent oral health care reduced the duration of SOM and reduced pediatric chemotherapy interruptions due to SOM by 81.8%. Conclusion: The permanent oral health care to offer to oncopediatric patients increased surveillance regarding oral comorbidities and reduced chemotherapy interruptions due to severe oral mucositis. This care plan could be adopted anywhere around the world. What is Known: • Several studies on oral care for pediatric oncology patients, especially regarding both prevention of and treatment for oral mucositis during antineoplastic therapy, have been published. What is New: • This study describes the benefits of permanent oral care with daily oral surveillance for pediatric patients, which reduced the duration of severe oral mucositis, increased surveillance and the efficiency in diagnostic for signs of oral mucositis, enabling early intervention, and decreased chemotherapy interruptions, contributing positively to the course of treatment.
The purpose of this study was to implement a model of permanent oral health care for oncopediatric patients and to observe its effects on severe oral mucositis and subsequent treatment interruptions. We performed a quasi-experimental study in the Pediatric Department of Napoleão Laureano Hospital, in the city of João Pessoa, Brazil. A integrated oral care was implemented by a dentistry team for prevention of comorbidities, such as infections, oral pain, oral function maintenance, oral mucositis, and interventions for lesions due to severe oral mucositis. The oral comorbidities were compared before and after the implementation. The duration of severe oral mucositis (SOM) before and after the interventions and the interruptions in treatment due to SOM were the main outcome measures. Permanent oral health care reduced the duration of SOM and reduced pediatric chemotherapy interruptions due to SOM by 81.8%. Conclusion: The permanent oral health care to offer to oncopediatric patients increased surveillance regarding oral comorbidities and reduced chemotherapy interruptions due to severe oral mucositis. This care plan could be adopted anywhere around the world. What is Known: • Several studies on oral care for pediatric oncology patients, especially regarding both prevention of and treatment for oral mucositis during antineoplastic therapy, have been published. What is New: • This study describes the benefits of permanent oral care with daily oral surveillance for pediatric patients, which reduced the duration of severe oral mucositis, increased surveillance and the efficiency in diagnostic for signs of oral mucositis, enabling early intervention, and decreased chemotherapy interruptions, contributing positively to the course of treatment.
Authors: Tim Staudenmaier; Irena Cenzer; Alexander Crispin; Helmut Ostermann; Karin Berger Journal: Support Care Cancer Date: 2017-12-02 Impact factor: 3.603
Authors: Sharon Elad; Judith E Raber-Durlacher; Michael T Brennan; Deborah P Saunders; Arno P Mank; Yehuda Zadik; Barry Quinn; Joel B Epstein; Nicole M A Blijlevens; Tuomas Waltimo; Jakob R Passweg; M Elvira P Correa; Göran Dahllöf; Karin U E Garming-Legert; Richard M Logan; Carin M J Potting; Michael Y Shapira; Yoshihiko Soga; Jacqui Stringer; Monique A Stokman; Samuel Vokurka; Elisabeth Wallhult; Noam Yarom; Siri Beier Jensen Journal: Support Care Cancer Date: 2014-09-05 Impact factor: 3.603
Authors: Isabella Lima Arrais Ribeiro; Sâmara Munique Silva; Rebecca Rhuanny Tolentino Limeira; Paulo Rogério Ferreti Bonan; Ana Maria Gondim Valença; Eufrásio Andrade de Lima Neto; Ricardo Dias de Castro Journal: J Appl Oral Sci Date: 2019-11-25 Impact factor: 2.698
Authors: Isabella Lima Arrais Ribeiro; Maria do Carmo Gullaci Guimarães Caccia-Bava; Maria Eduarda Alves Sampaio; Rebecca Rhuanny Tolentino Limeira; Laís Guedes Alcoforado de Carvalho; Fabio Gomes Dos Santos; Paula Maria Maracajá Bezerra; Simone Alves Sousa; Ana Maria Gondim Valença Journal: J Cancer Educ Date: 2022-08-27 Impact factor: 1.771
Authors: Maria Eduarda Alves Sampaio; Isabella Lima Arrais Ribeiro; Bianca Marques Santiago; Ana Maria Gondim Valença Journal: Asian Pac J Cancer Prev Date: 2022-02-01